Cantor Fitzgerald Rates Tenax Therapeutics (TENX) buy
Cantor Fitzgerald maintains its buy rating on Tenax Therapeutics with a $35 price target, a 171.53% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Cantor Fitzgerald rated Tenax Therapeutics, Inc. ($TENX) "buy" with a $35 price target on June 24, 2026.
Since the rating, $TENX is up 2.8% after 1 week, up 12.4% after 1 month and down 89.5% to date (from the $12.93 close on Jun 24, 2026).
TENX
Tenax Therapeutics, Inc.
Key Points
- Cantor Fitzgerald reiterated its buy rating for Tenax Therapeutics (TENX) on June 24, 2026, with a price target of $35.
- Cantor Fitzgerald's $35 price target implies 171.53% upside from Tenax Therapeutics, Inc.'s ($TENX) current $12.89 share price.
- Tenax Therapeutics shares traded at $13.64 on Wednesday, with a market cap of about $324.9 million and a 52-week range between $5.62 and $18.38.
- Peers like Janus Henderson and Stonepine Capital have shown significant interest, with Stonepine increasing its stake by 8106% to 975,200 shares.
Get $TENX trade alerts by text
We text you when insiders, Congress or big funds trade $TENX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Tenax Therapeutics, Inc. alert may contain errors. Disclosures
Cantor Fitzgerald reiterated its buy rating for Tenax Therapeutics, Inc. (NasdaqCM:TENX) on June 24, 2026. The firm set a price target of $35 for the biotechnology company, which specializes in novel cardiopulmonary therapies. Shares of Tenax were trading at $13.64 on Wednesday.
Cantor Fitzgerald vs. the S&P 500
Hypothetical returns from Cantor Fitzgerald's disclosed trades, not real profit or advice. How we model this.
Tenax Therapeutics, Inc. Stock Up 578.4%
Shares of Tenax Therapeutics traded near $13.64 on Wednesday. The company has a market cap of approximately $324.9 million. With a 52-week low of $5.62 and a high of $18.38, the stock is currently trading closer to its higher range. Tenax's 50-day moving average is $12.47, while its 200-day moving average stands at $11.05. The company maintains a strong current ratio of 14.52 and a quick ratio of 13.99, reflecting its ability to cover short-term liabilities.
$TENX price target
Tenax Therapeutics, Inc. daily closes and this analyst's $35 target. Not advice.
Analysts Set New Price Targets
On June 24, 2026, Cantor Fitzgerald reiterated its buy rating on Tenax Therapeutics with a $35 price target. Earlier, on June 22, Guggenheim maintained its buy rating with a target of $40, and Chardan Capital initiated coverage with a buy rating and a $27 target. Piper Sandler also maintained a buy rating with a $50 target on June 12. The consensus among analysts is a strong buy, with an average target price of $34 based on seven analyst opinions.
Other Institutional Activity in Tenax Therapeutics
Several institutional investors have been active in Tenax Therapeutics. Janus Henderson Group PLC increased its holdings by 1,648,808 shares, bringing its total to 1,815,474 shares worth about $29.1 million, marking a 989.3% increase. Stonepine Capital Management, LLC significantly boosted its position by 963,316 shares, ending with 975,200 shares valued at approximately $15.6 million, an 8106% increase. New positions were opened by Price T Rowe Associates Inc /MD/ and Venrock Adviser, LLC, with each acquiring over a million shares.
Insider Buying and Selling at Tenax Therapeutics, Inc.
Recent insider transactions at Tenax Therapeutics include significant purchases by Thomas Staab II, the Chief Financial Officer, who bought a total of 460,000 shares on May 11, 2026. Interim CFO Thomas McGauley also acquired 100,000 shares in two separate transactions on January 30, 2026. Additionally, Declan Doogan and Michael Davidson each purchased 30,000 shares on January 9, 2026.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina. The company focuses on developing treatments for cardiopulmonary conditions. Its key products include TNX-101, TNX-102, and TNX-103, which are in development for treating pulmonary hypertension in heart failure patients. Tenax also works on TNX-201, aimed at treating chronic myeloid leukemia. The company, led by CEO Christopher T. Giordano, employs 14 people.
Bottom Line
Cantor Fitzgerald's reiteration of a buy rating with a $35 target price underscores confidence in Tenax Therapeutics' potential. Investors should note that institutional activities and insider transactions can provide insights into market sentiment. As always, 13F filings and analyst ratings offer a backward-looking view and may not reflect current positions or future performance.
Related Filing Alerts
Source: Cantor Fitzgerald's rating change on $TENX (Jun 24, 2026). Written by software, not financial advice. How we make alerts